Latest Immunohistochemistry Stories
TUCSON, Jan. 10, 2012 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced that it has entered into a collaboration agreement with Pfizer Inc. and license agreement with Cell Signaling Technology (CST) to develop the first fully automated and standardized immunohistochemistry (IHC) companion diagnostic test for ALK gene rearrangements. Ventana will develop the test which is intended to identify non-small cell lung cancer...
BRANFORD, Conn., Dec. 21, 2011 /PRNewswire/ -- HistoRx recently licensed from Yale University a new clinical diagnostic assay based on AQUA® technology. This assay enables doctors treating patients with melanoma to identify a subset of those patients who, despite having no detectable cancer in their lymph nodes, have a 40% risk of recurrence of their disease. AQUA technology is an automated, quantitative IHC testing method that enables measurement of protein biomarkers in...
TUCSON, Ariz., Dec. 13, 2011 /PRNewswire/ -- Ventana Medical Systems Inc. (Ventana), a member of the Roche Group, and Advanced Cell Diagnostics Inc. (ACD), announced today they have entered a worldwide co-promotion agreement for the first commercially available, fully automated RNA in situ hybridization (ISH) assay system capable of robust detection and visualization of virtually any expressed gene in routine clinical specimens at single-molecule sensitivity. (Photo:...
IRVINE, Calif., Nov. 29, 2011 /PRNewswire/ -- GeneTex, a leading manufacturer of antibodies and antibody-related reagents, is pleased to announce that they will be launching a new line of antibodies against Hice1 and Hec1. Both of these targets are key players in spindle assembly. (Photo: http://photos.prnewswire.com/prnh/20111129/LA13485-a) (Logo: http://photos.prnewswire.com/prnh/20111129/LA13485LOGO-b) Hice1 is a novel microtubule-associated protein that is required for the...
BRANFORD, Conn., Oct. 6, 2011 /PRNewswire/ -- HistoRx, the leader in quantitative immunohistochemistry, advances its proprietary position in digital pathology through the recent issuance of US patents covering key features necessary for achievement of reproducible, standardized image analysis results. The U.S. Patent and Trademark Office has granted two new patents protecting the company's methods for standardization of digital microscopy instruments, methods required to generate...
TUCSON, Ariz., Oct. 4, 2011 /PRNewswire/ -- The VENTANA anti-Helicobacter pylori (SP48) Rabbit Monoclonal Primary Antibody (H. pylori) is the first H. pylori antibody to receive 510(k) clearance from the Food and Drug Administration (FDA). Developed by Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, the VENTANA H. pylori antibody, when used in immunohistochemical (IHC) staining, aids in the detection of Helicobacter pylori, a bacterium linked to chronic gastritis,...
Researchers have determined that a combination of P16 immunohistochemistry and DNA qPCR to test for viral E6 can accurately determine the oropharyngeal squamous cell carcinoma, a form of head and neck cancer, which derive from HPV16, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research. "This has immediate clinical applications as we consider recruitment to clinical trials designed to de-escalate the intensity of therapy...
TUCSON, Ariz., Sept. 12, 2011 /PRNewswire/ -- University Medical Center in Tucson (UMC) is validating the VENTANA INFORM HER2 Dual ISH DNA Probe cocktail assay (HER2 Dual ISH) on the BenchMark XT automated slide staining instrument to help determine HER2 gene status in breast cancer patients in an effort to change the paradigm for targeted treatment therapies. The assay, developed by Ventana Medical Systems, Inc. (Ventana), a member of the Roche group, is the first fully automated assay...
IRVINE, Calif., Aug. 23, 2011 /PRNewswire/ -- GeneTex, a leading manufacturer of high quality antibodies, has launched several new specials on products from their large catalog containing more than 40,000 primary and secondary antibodies, DNA damage antibodies, proteins, peptides, and research reagents. Plus, GeneTex is introducing over 15,000 ELISA kits for quantitative measurements of proteins including cytokines, interleukins, growth factors, hormones, coagulation factors, and targets...
TUCSON, Ariz., Aug. 2, 2011 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, announced today the launch of BenchMark ULTRA with new Ultimate Reagent Access (URA). BenchMark ULTRA with URA is the world's first platform that allows laboratories to process individual immunohistochemistry (IHC) and in situ hybridization (ISH) samples as soon as they arrive in the lab. This enhancement allows labs to quickly respond to unpredictable changes in workflow,...
